Related Experiment Video

Updated: Aug 3, 2026

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy
12:24

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy

Published on: September 29, 2016

Signal transduction inhibition: changing paradigms in cancer care

C A Schiffer1

  • 1Barbara Ann Karmanos Cancer Center Institute, Wayne State University School of Medicine, Detroit, MI, USA.

Seminars in Oncology
|December 12, 2001
PubMed

Insights

The targeted therapy imatinib mesylate (Gleevec) offers new treatment options for chronic myeloid leukemia and other cancers. Its rapid development highlights the need for careful information dissemination and further research into optimal usage.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • Imatinib mesylate (Gleevec) represents a significant advancement in targeted cancer therapy.
  • The drug's development and approval process offers valuable lessons for regulatory agencies and researchers.
  • Patient access to information, particularly online, has increased, empowering them in treatment decisions.

Purpose of the Study:

  • To discuss the impact of imatinib mesylate on cancer treatment paradigms.
  • To highlight the challenges and lessons learned from the rapid development and approval of targeted therapies.
  • To emphasize the evolving role of patients in their healthcare journey.

Main Methods:

  • Review of the development and clinical impact of imatinib mesylate.
  • Analysis of the regulatory and information dissemination processes surrounding novel cancer drugs.
  • Consideration of the patient's perspective in the era of personalized medicine.

Main Results:

  • Imatinib mesylate has transformed treatment for chronic myeloid leukemia and gastrointestinal stromal tumors.
  • The accelerated pace of drug development necessitates robust strategies for managing information and avoiding misinformation.
  • Patients are increasingly informed and active participants in their cancer care.

Conclusions:

  • Further clinical trials are essential to determine the optimal use of imatinib mesylate.
  • The success of imatinib mesylate underscores the potential of targeted therapies in oncology.
  • Effective communication and education are crucial for navigating breakthroughs in cancer treatment.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...